CSL Announces Strategic Initiatives to Drive Growth and Simplification
CSL Limited, a global biotherapeutics leader, has announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant currency basis. Underlying profit (NPATA) was US$3.3 billion, up 14% on a constant currency basis. The company’s Chief Executive Officer and Managing Director, Dr. Paul … Read more